Skip to Main Content

Paper Details

Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Gynecol Oncol
8
2022
/neu gene amplification, ARK1, ARK2, ARK4, HER2, HER2/neu 1+ tumors, HER2/neu 3+ cell lines, HRD, Homologous recombination deficiency, Neratinib, PARP, USC, USC cell lines, USC cells, USC xenografts, USC-xenografts, Uterine serous carcinoma, c, c-erb, endometrial cancer, neratinib, neu, neu 1, olaparib, patients, poly (ADP-ribose), poly (ADP-ribose)-polymerase, trastuzumab, tumor, tumors, uterine serous carcinoma
Author NameAffiliation
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine University of California San Diego
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine University of California San Diego
  • 1 - 2

Datasets

Release 1.2